EMPLOYMENT AGREEMENTEmployment Agreement • January 19th, 2021 • Adagene Inc. • Pharmaceutical preparations • New York
THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into, by and between Adagene Inc., a company incorporated and existing under the laws of the Cayman Islands (the “Company” and, together with all of its direct or indirect parent companies, subsidiaries, affiliates, or subsidiaries or affiliates of its parent companies, collectively referred to as the “Company Group”), and , an individual (the “Executive”). This Agreement is effective as of the Hire Date (as defined below) (the “Effective Date”).
SHARE PURCHASE AGREEMENTShare Purchase Agreement • January 19th, 2021 • Adagene Inc. • Pharmaceutical preparations • Hong Kong
NOW, THEREFORE, in consideration of the foregoing recitals, the mutual promises hereinafter set forth, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties intending to be legally bound hereto hereby agree as follows:
FIFTH AMENDED AND RESTATED SHAREHOLDERS AGREEMENT by and among ADAGENE INC. AND ITS SUBSIDIARIES ORDINARY SHAREHOLDERS NAMED HEREIN SERIES A SHAREHOLDERS NAMED HEREIN SERIES B SHAREHOLDERS NAMED HEREIN AND SERIES C SHAREHOLDERS NAMED HEREIN DECEMBER...Shareholder Agreement • January 19th, 2021 • Adagene Inc. • Pharmaceutical preparations • Hong Kong
Each of the parties to this Agreement is referred to herein individually as a “Party” and collectively as the “Parties”. Capitalized terms used herein without definition shall have the meanings set forth in the Share Purchase Agreement (as defined below).
LICENSE AGREEMENT AMONG ADC THERAPEUTICS SA AND ADAGENE Inc.License Agreement • January 19th, 2021 • Adagene Inc. • Pharmaceutical preparations • York
THIS LICENSE AGREEMENT (“License Agreement”) is made and entered into as of April 11, 2019 (“Execution Date”), by and between ADC THERAPEUTICS SA, a company having an address at Route de la Corniche 3B, 1066 Epalinges, Switzerland (“ADCT”), ADAGENE Inc. a Cayman company having an address at Grand Pavilion, Hibiscus Way, 802 West Bay Road, P.O. Box 31119, KY1-1205, Cayman Islands (the “Adagene”), ADAGENE also acting on behalf and for the account of its affiliated companies, including in the USA and in PRC, as listed in Annex 6 (individually “ADAGENE Affiliate” and collectively “ADAGENE Affiliates”). ADCT and ADAGENE are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
Dragon Boat Biopharmaceutical (Shanghai) Limited. AND Adagene Inc. Cooperation Agreement on International Interests of [***] Project May 2019Cooperation Agreement • January 19th, 2021 • Adagene Inc. • Pharmaceutical preparations
This Cooperation Agreement on International Interests of [***] Project (this “Agreement”) is made and entered into by and among the following Parties on May 22, 2019 in Shanghai, the People’s Republic of China (“China” or the “PRC”):
FOURTH AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENTRight of First Refusal and Co-Sale Agreement • January 19th, 2021 • Adagene Inc. • Pharmaceutical preparations • Hong Kong
Dragon Boat Biopharmaceutical (Shanghai) Limited. AND Adagene (Suzhou) Limited Cooperation Agreement on the [***] Project May 2019Cooperation Agreement • January 19th, 2021 • Adagene Inc. • Pharmaceutical preparations
This Cooperation Agreement on the [***] Project (this “Agreement”) is made and entered into by and among the following parties on May 22, 2019 in Shanghai, the People’s Republic of China (“China” or the “PRC”):
FORM OF INDEMNIFICATION AGREEMENTIndemnification Agreement • January 19th, 2021 • Adagene Inc. • Pharmaceutical preparations • Hong Kong
THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of , 20 between (i) Adagene Inc., an exempted company organized under the laws of the Cayman Islands (the “Company”) and (ii) , an individual holding a numbered serving as [ of the Company (the “Officer”)]/[a director of the Company (the “Director”)]. The [Officer/Director] shall be referred to herein as the “Indemnitee”.
Guilin Sanjin Pharmaceutical Co., Ltd. AND Adagene (Suzhou) Limited Cooperation Agreement on the PD-L1 Project December 2018Cooperation Agreement • January 19th, 2021 • Adagene Inc. • Pharmaceutical preparations
This Cooperation Agreement on the PD-L1 Project (this “Agreement”) is made and entered into by and among the following parties on December 27, 2018 in Shanghai, the People’s Republic of China (“China” or the “PRC”):
CONFIDENTIAL MATERIAL TRANSFER AND COLLABORATION AGREEMENTMaterial Transfer and Collaboration Agreement • January 19th, 2021 • Adagene Inc. • Pharmaceutical preparations • New York
This Material Transfer and Option Agreement (“Agreement”), is made on April 11, 2019 (“Effective Date”) and is entered into by and between ADC THERAPEUTICS SA, a company having an address at Route de la Corniche 3B, 1066 Epalinges, Switzerland (“ADCT”), ADAGENE Inc., a Cayman company having an address at Grand Pavilion, Hibiscus Way, 802 West Bay Road, P.O. Box 31119, KY1-1205, Cayman Islands, (“ADAGENE”), ADAGENE also acting on behalf and for the account of its affiliated companies, including in the USA and in PRC, as listed in Annex 7 (individually “ADAGENE Affiliate” and collectively as “ADAGENE Affiliates”). ADCT and ADAGENE are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
Guilin Sanjin Pharmaceutical Co., Ltd. AND Adagene Inc. Cooperation Agreement on International Interests of PD-L1 Project December 2018Cooperation Agreement • January 19th, 2021 • Adagene Inc. • Pharmaceutical preparations
This Cooperation Agreement on International Interests of PD-L1 Project (this “Agreement”) is made and entered into by and among the following Parties on December 27, 2018 in Shanghai, the People’s Republic of China (“China” or the “PRC”):
